维普中文期刊产品整合服务
51篇 您的检索式:作者名="KOSTAS P"
    题名 作者 年代 出处 被引量
1Emotion recognition through facial expression analysis based on a neurofuzzy network显示文摘Spiros V Ioannou Amaryllis T RaouzAiou Vasilis A Tzouvaras Theofilos P MAilis Kostas C Karpouzis Stefanos D Kollias 2005Neural Networks2005,,:1
2Multiband metamaterial truncated square microstrip-based radiating structure design 显示文摘SHOBHIT K PATEL KOSTA Y P 2014Wave Random Complex Media2014,24,1:1
3Subsite-specific differences of es trogen receptor beta expression in the normal colonic epithelium : implications for carcinogenesis anti colorectal cancer epidemiology 显示文摘Kostis P Kostas T Annie J 2010Eur J Gastroenterol Hepatol2010,22,5:1
4Subsite-speeific differences of estrogen receptor beta expression in the normal colonic epithelium:implications for carcinogenesis and colorectal cancer epidemiology显示文摘Kostis P Kostas T Annie J 2010Eur J Gastroenterol Hepatol2010,22,8:1
5Economics of exhaust air heat recovery systems for mine ventilation显示文摘Hugo D S Kostas F Jacek P 2012Reclamation and Environment2012,26,3:1
6Outcome of patients with diffuse axonal injury:the significance and prognostic value of MRI in the aute phase显示文摘Kostas P Apostolos H Karantanas 2000J Trauma2000,49,:1
7MRI evaluation of the basal ganglia size and iron content in patients with Parkinson′s disease显示文摘Kosta P Argyropoulou MI Markoula S 2006J Neurol2006,253,1:1
8Behaviour A- nalysis of Multilayer Perceptrons with Multiple Hidden Neurons and Hidden Layers显示文摘GPanchal A Ganatra Y P Kosta and D Panchal 2011International Journal of Computer Theory and Engineering2011,3,2:1
9Diffusion tensor and dynamic susceptibility contrast MRI in glioblastoma显示文摘ZIKOU A K ALEXIOU G A KOSTA P 2012Clin Neurol Neurosurg2012,114,6:1
10Laboratory evaluation of Fe0 barriers to treat acidic leachates 显示文摘Georgios B Kostas K Ioannis P 2006Minerals Engineering2006,19,5:1
11α2-Heremans-schmid glycoprotein(fetuin A)downregulation and its utility in inflammatory bowel disease显示文摘AIM To investigate the impact of inflammatory bowel disease (IBD) on α2-Heremans-Schmid Glycoprotein(AHSG/fetuin A) and potential associations with disease and patient characteristics.METHODS AHSG serum levels were determined in treatment-na?ve newly-diagnosed patients, 96 with ulcerative colitis(UC), 84 with Crohn's disease (CD), 62 with diarrheapredominant or mixed irritable bowel syndrome (IBS, D- and M- types) and 180 healthy controls (HC), by an enzyme linked immunosorbent assay (ELISA).All patients were followed for a minimum period of 3 years at the Gastroenterology Department of the University Hospital of Larissa, Greece. C-reactive protein(CRP), anti-glycan antibodies, anti-Saccharomyces cerevisiae mannan antibodies Ig G, anti-mannobioside carbohydrate antibodies Ig G, anti-laminariobioside carbohydrate antibodies Ig G and anti-chitobioside carbohydrate antibodies Ig A were also determined via immunonephelometry and ELISA, respectively.RESULTS The mean ± SE of serum AHSG, following adjustment for confounders, was 0.32 ± 0.02 g/L in IBD, 0.32 ± 0.03 g/L in CD and 0.34 ± 0.03 g/L in UC patients, significantly lower than in IBS patients(0.7 ± 0.018 g/L) and HC (0.71 ± 0.02 g/L) (P < 0.0001, in all cases). AHSG levels were comparable between the CD and UC groups. Based on AHSG levels IBD patients could be distinguished from HC with about 90% sensitivity and specificity. Further adjusted analysis verified the inverse association between AHSG and penetrating, as well as stricturing CD (partial correlation coefficient: -0.45 and -0.33, respectively) (P < 0.05). After adjusting for confounding factors, inverse correlations between AHSG and CRP and the need for anti-TNFα therapy or surgery, were found (partial correlation coefficients:-0.31,-0.33,-0.41, respectively, P < 0.05, in all cases). Finally, IBD individuals who were seropositive, for at least one marker, had AHSG levels falling within the two lower quartiles (OR = 2.86, 95%CI: 1.5-5.44, P < 0.001) while those with at least two serological markers positive exhibited AHSG concentrations within the lowest quartile (OR = 5.03, 95%CI: 2.07-12.21, P < 0.001), after adjusting for age, sex and smoking.CONCLUSION AHSG can be used to distinguish between IBD and IBS patients or HC while at the same time 'predicting' complicated disease behavior, need for therapy escalation and surgery. Moreover, AHSG may offer new insights into the pathogenesis of IBD, since it is involved in key processes.Anastassios C Manolakis Gregory Christodoulidis Andreas N Kapsoritakis Panagiotis Georgoulias Elisavet K Tiaka Kostas Oikonomou Varvara J Spyros P Potamianos 2017World Journal of Gastroenterology2017,23,3:1
12Marchiafava-Bignami disease: an acquired callosotomy显示文摘Lakatoss A Kosta P Konitsiotis S 2014Neurology2014,83,13:1
13Heterotopic ossification of the knee joint in intensive care unit patients: early diagnosis with magnetic resonance imaging 显示文摘Argyropoulou MI Kostandi E Kosta P 2006Critical Care2006,10,:1
14MRI evaluation of the basal ganglia size and iron content in patients with Parkin- son: disease 显示文摘Kosta P Argyropoulou MI Markoula S 2006J Neurol2006,253,1:1
15Model predictive direct torque control—Part Ⅱ:implementation and experimental evaluation显示文摘Papafotiou G Kley J Kostas G P 0,,06:1
16The effects of treatment with octreotide, diuretics, or both on portal hemodynamics in nonazotemic cir- rhotic patients with ascites显示文摘Kalambokis G Economou M Kosta P 2006J Clin Gastroentero12006,40,4:1
17Conceptus radiation dose and risk from chest screen-film radiography显示文摘John D Kostas P Panos P 2003Eur Radiol2003,13,3:1
18MRI evaluation of the basal ganglia size and iron content in patients with Parkinson's disease 显示文摘Kosta P Argyropoulou MI Markoula S 2006J Neurol2006,253,1:1
19Meehanisrns of mammali-an iron homeostasis显示文摘Kostas P Suheel K P Alan T et M 2012Biochemistry2012,51,:1
20MarchiafavaBignami disease:an acquired callosotomy显示文摘Lakatoss A Kosta P Konitsiotis S 2014Neurology2014,83,13:1
返回顶部 每页显示:
共3页 首页 上一页 第1页 下一页 末页 /3 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费